Last updated on March 2018

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

Brief description of study

The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a novel mechanism of action in immunocompromised adults with invasive aspergillosis.

Detailed Study Description

To compare the safety and efficacy of VL-2397 to standard first-line treatment for invasive aspergillosis in immunocompromised adults with acute leukemia or recipients of an allogeneic hematopoietic cell transplant (allo-HCT).

Clinical Study Identifier: NCT03327727

Contact Investigators or Research Sites near you

Start Over

Aprile Osborn, RN

Medical College of Georgia at Augusta University
Augusta, GA United States
  Connect »

Shelbie Martin

The University of Texas Health Science Center - Houston
Houston, TX United States
  Connect »